Mergers and Acquisitions

Select Therapeutics, Cytomatrix, Terminate Their Joint Venture

Published in Vaccine Weekly, November 21st, 2001

Select Therapeutics, Inc., and Cytomatrix, LLC have agreed to terminate their Joint Venture, Cell Science Therapeutics, Inc.

Given the extremely difficult economic circumstances since September of this year (2001), each company believes that shareholder value may be best protected by dividing CST development activities into separate cell therapeutic and drug and vaccine companies, which can each seek appropriate financing. Both companies plan to cooperate in areas of mutual interest and may enter into appropriate collaborative agreements in the future as opportunities arise.

Provisions of the restructuring include:

the return of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry